Back to top

CureVac downgraded to Neutral from Buy at UBS

UBS downgraded CureVac (CVAC) to Neutral from Buy with a price target of $5.50, down from $12. BioNTech (BNTX) announced the acquisition of CureVac...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

CureVac N.V. (CVAC)